Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANEB NASDAQ:KTTA NASDAQ:QNCX NASDAQ:RNAZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.40+11.0%$0.52$0.30▼$3.42$16.31M-1.8845,923 shs2,235 shsKTTAPasithea Therapeutics$0.58+0.8%$0.73$0.28▼$2.06$14.35M0.25442,813 shs300,135 shsQNCXQuince Therapeutics$0.97-3.0%$1.20$0.79▼$45.50$16.30M1.42.00 million shs804,915 shsRNAZTransCode Therapeutics$4.98-2.2%$7.34$3.82▼$20.99$4.84M1.28142,277 shs20,547 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-3.95%-16.23%-26.89%-19.96%-66.65%KTTAPasithea Therapeutics-1.61%-19.50%-27.62%-29.67%-35.02%QNCXQuince Therapeutics-0.99%-9.91%-21.88%-3.85%-91.45%RNAZTransCode Therapeutics-9.11%-5.57%-30.46%-47.31%-28.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANEBAnebulo Pharmaceuticals$0.40+11.0%$0.52$0.30▼$3.42$16.31M-1.8845,923 shs2,235 shsKTTAPasithea Therapeutics$0.58+0.8%$0.73$0.28▼$2.06$14.35M0.25442,813 shs300,135 shsQNCXQuince Therapeutics$0.97-3.0%$1.20$0.79▼$45.50$16.30M1.42.00 million shs804,915 shsRNAZTransCode Therapeutics$4.98-2.2%$7.34$3.82▼$20.99$4.84M1.28142,277 shs20,547 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANEBAnebulo Pharmaceuticals-3.95%-16.23%-26.89%-19.96%-66.65%KTTAPasithea Therapeutics-1.61%-19.50%-27.62%-29.67%-35.02%QNCXQuince Therapeutics-0.99%-9.91%-21.88%-3.85%-91.45%RNAZTransCode Therapeutics-9.11%-5.57%-30.46%-47.31%-28.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANEBAnebulo Pharmaceuticals 1.50ReduceN/AN/AKTTAPasithea Therapeutics 2.00Hold$3.00417.24% UpsideQNCXQuince Therapeutics 1.71Reduce$65.006,601.03% UpsideRNAZTransCode Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest RNAZ, QNCX, ANEB, and KTTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/1/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/1/2026QNCXQuince Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026RNAZTransCode Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026KTTAPasithea Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.004/2/2026KTTAPasithea Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/27/2026KTTAPasithea Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANEBAnebulo PharmaceuticalsN/AN/AN/AN/A$0.28 per shareN/AKTTAPasithea TherapeuticsN/AN/AN/AN/A$2.39 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A($6.41) per shareN/ARNAZTransCode TherapeuticsN/AN/AN/AN/A$11.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANEBAnebulo Pharmaceuticals-$8.48M-$0.19N/AN/AN/AN/A-74.57%-68.96%N/AKTTAPasithea Therapeutics-$20.43M-$2.08N/AN/AN/AN/A-57.44%-53.61%8/13/2026 (Estimated)QNCXQuince Therapeutics-$83.98M-$10.62N/AN/AN/AN/A-372.88%-67.99%8/11/2026 (Estimated)RNAZTransCode Therapeutics-$34.66M-$50.33N/AN/AN/AN/A-875.35%-50.36%8/18/2026 (Estimated)Latest RNAZ, QNCX, ANEB, and KTTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026KTTAPasithea Therapeutics-$0.45-$0.12+$0.33-$0.12$0.10 millionN/A5/15/2026Q1 2026RNAZTransCode TherapeuticsN/A-$21.28N/A-$21.28N/AN/A5/11/2026Q1 2026QNCXQuince Therapeutics-$1.30-$0.59+$0.71$2.88N/AN/A3/30/2026Q4 2025KTTAPasithea Therapeutics-$0.18-$0.89-$0.71-$0.89$0.10 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANEBAnebulo PharmaceuticalsN/AN/AN/AN/AN/AKTTAPasithea TherapeuticsN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANEBAnebulo PharmaceuticalsN/A6.246.24KTTAPasithea TherapeuticsN/A35.4135.41QNCXQuince TherapeuticsN/A2.922.92RNAZTransCode TherapeuticsN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANEBAnebulo Pharmaceuticals28.40%KTTAPasithea Therapeutics23.92%QNCXQuince Therapeutics30.75%RNAZTransCode TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANEBAnebulo Pharmaceuticals80.60%KTTAPasithea Therapeutics2.00%QNCXQuince Therapeutics7.10%RNAZTransCode Therapeutics0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANEBAnebulo Pharmaceuticals440.79 million7.91 millionNot OptionableKTTAPasithea Therapeutics324.94 million24.44 millionNot OptionableQNCXQuince Therapeutics6016.30 million15.14 millionOptionableRNAZTransCode Therapeutics9950,000949,000Not OptionableRNAZ, QNCX, ANEB, and KTTA HeadlinesRecent News About These CompaniesRNAZ: Introducing RNA therapeuticsJune 8 at 1:00 PM | msn.comTransCode Therapeutics to Host R&D Webcast on June 18, 2026June 8 at 8:04 AM | prnewswire.comRNAZ Share News TodayJune 4, 2026 | uk.investing.comEXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 StudyJune 3, 2026 | finance.yahoo.comTransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic CancerJune 3, 2026 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal CancerMay 28, 2026 | finanznachrichten.deTransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal CancerMay 27, 2026 | prnewswire.comTransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State UniversityApril 27, 2026 | prnewswire.comTransCode Therapeutics signs financing deal worth up to $20 millionApril 8, 2026 | msn.comTransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028April 7, 2026 | prnewswire.comTransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer PatientsMarch 3, 2026 | prnewswire.comTransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further DevelopmentFebruary 23, 2026 | prnewswire.comTransCode Therapeutics Advances Phase 2a Colorectal Cancer TrialFebruary 11, 2026 | theglobeandmail.comTransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138February 5, 2026 | finanznachrichten.deTransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138February 5, 2026 | prnewswire.comTransCode Therapeutics reports promising preclinical glioblastoma resultsJanuary 6, 2026 | msn.comTransCode Therapeutics stock soars after promising glioblastoma studyJanuary 6, 2026 | uk.investing.comTransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in GlioblastomaJanuary 6, 2026 | prnewswire.comTransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of DirectorsDecember 22, 2025 | prnewswire.comTransCode Therapeutics, Inc.: TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive ...December 11, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNAZ, QNCX, ANEB, and KTTA Company DescriptionsAnebulo Pharmaceuticals NASDAQ:ANEB$0.40 +0.04 (+10.99%) As of 11:31 AM EasternAnebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.Pasithea Therapeutics NASDAQ:KTTA$0.58 +0.00 (+0.76%) Closing price 04:00 PM EasternExtended Trading$0.58 0.00 (-0.69%) As of 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.Quince Therapeutics NASDAQ:QNCX$0.97 -0.03 (-3.00%) Closing price 04:00 PM EasternExtended Trading$0.99 +0.02 (+1.96%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.TransCode Therapeutics NASDAQ:RNAZ$4.98 -0.11 (-2.16%) Closing price 03:59 PM EasternExtended Trading$5.00 +0.02 (+0.38%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Corning Is Paving AI's Future With Glass The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? From Crypto to AI: Insiders Are Trading These 3 Stocks The Case for Intel Over Pure-Play Quantum Firms Has Temu-Owner PDD's Story Changed After Double Miss? Campbell's Soup Stock: Deep Value and a 7% Dividend Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
